How Podcasting Is Fueling Sophia Kianni And Phoebe Gates’ Fashion Startup Phia https://t.co/03Nf10lKOe https://t.co/nqt237FyNX ...

DeepSeek-R1 爆火后，类 R1 的结果奖励训练范式在各领域掀起了推理热潮。基于规则的结果奖励实现简单、判断严格。但是，这真的够了吗？ 在推理任务中，如果我们只是用「结果对错」来奖励模型，那模型就很可能学会了「靠捷径答题」。 这种模式下，模型的「正确思考策略」没有完全建立起来，它甚至会因为一次「瞎蒙对」的奖励，而在之后反复强化错误策略，越走越偏。 为了解决这个问题，港中文联合上海人工智能实验室团队发布了多模态推理模型 SophiaVL-R1，它在类 R1 强化学习训练框架上做了一次关键进化：不再 只奖励结果是否正确，而是将「思考过程」也纳入奖励体系。 这一套设计不仅能让模型学会更通用、更靠谱的推理策略，还显著提升了泛化能力——在多个数学和通用多模态基准测试中，SophiaVL-R1-7B 甚至击败 了参数量是其 10 倍的 LLaVA-OneVision-72B 模型。 目前，研究团队已将所有模型、数据和代码开源。 思考过程也要评分，才是好模型 SophiaVL-R1 的关键突破点，就在于它引入了「思考奖励」机制 —— 不再只看答案对不对，而是开始评估模型整个推理过程是否合理、连贯、靠谱。 论文链接： ...

ATHENS, Greece, May 27, 2025 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today announced that through a separate wholly-owned subsidiary, it has entered into a time charter contract with Refined Success Limited, for one of its Newcastlemax dry bulk vessels, the m/v Philadelphia. The gross charter rate is US$21,500 per day, minus a 5.00% commission paid to third parties, for a period ...

Core Insights - Lincoln Educational Services Corporation (LINC) reported strong first-quarter 2025 results, with earnings and revenues exceeding the Zacks Consensus Estimate, marking the sixth consecutive quarter of double-digit growth [1][3] Financial Performance - Adjusted earnings per share were 11 cents, surpassing the Zacks Consensus Estimate of 4 cents by 175% and increasing 83.3% year-over-year [3] - Total revenues reached $117.5 million, exceeding the consensus estimate of $114 million by 3.2% and rising 13.7% from the previous year [3] - Adjusted EBITDA was $10.6 million, reflecting a year-over-year increase of 62.5% [5] Student Enrollment - Student starts (excluding the Transitional segment) grew by 20.9% to 4,610, while the quarter-end student population rose 18.3% to 15,904 compared to the previous year [4] - The average student population increased to 15,469 from 13,311 a year ago [4] Expenses and Cash Flow - Selling, general and administrative expenses increased by 10.6% year-over-year to $66.9 million, primarily due to costs related to new programs and campuses [4] - Cash and cash equivalents as of March 31, 2025, were $28.7 million, down from $59.3 million as of December 31, 2024 [7] Guidance and Projections - LINC raised its 2025 revenue guidance to between $485 million and $495 million, up from the previous range of $480-$490 million [8] - Adjusted EBITDA is now expected to be in the range of $58-$63 million, an increase from the earlier expectation of $55-$60 million [8] - Student starts growth is projected in the 10-14% range, up from the previous expectation of 8-12% [9]

Core Insights - American Public Education, Inc. (APEI) reported strong first-quarter 2025 results, with adjusted earnings and total revenues exceeding expectations and showing year-over-year growth [1][2] - The performance was primarily driven by contributions from Rasmussen University (RU), American Public University System (APUS), and Hondros College of Nursing (HCN), while the Graduate School (GSUSA) segment experienced a revenue decline [1][2] Financial Performance - APEI's adjusted earnings per share (EPS) reached 41 cents, significantly surpassing the Zacks Consensus Estimate of 15 cents by 173.3%, compared to a loss of six cents per share in the same quarter last year [3] - Total revenues amounted to $164.6 million, exceeding the consensus mark of $162 million by 1.6% and growing 6.6% year over year, supported by net course registration growth and tuition increases [4] - Total costs and expenses rose 2% year over year to $152.3 million, driven by a 3.5% increase in instructional costs and an 8.5% rise in selling and promotional expenses [4] - Adjusted EBITDA increased by 24% year over year to $21.2 million, with an adjusted EBITDA margin of 13%, expanding 200 basis points from 11% [5] Segment Performance - APUS reported revenues of $83.9 million, a 4.1% increase from $80.7 million year over year, driven by net course registrations and tuition increases [6] - RU's revenues grew 11.5% year over year to $59.3 million, attributed to enrollment growth and tuition hikes, with total student enrollment increasing 7.4% to 14,500 [7][8] - HCN's revenues rose 7.5% year over year to $17.7 million, supported by student enrollment growth, although it reported a negative EBITDA margin of 1% [8][9] - GSUSA's revenues declined 11.9% year over year to $3.7 million, with a negative EBITDA margin of 57% [10] Cash and Debt Position - As of March 31, 2025, APEI had cash, cash equivalents, and restricted cash of $187.5 million, up from $158.9 million at the end of 2024 [11] - Net long-term debt slightly increased to $93.7 million from $93.4 million at the end of 2024 [11] Guidance and Outlook - For Q2 2025, APEI expects total revenues to increase by 4-5% year over year to $160-$162 million, with a projected loss per share between 13 cents and four cents [12] - Adjusted EBITDA for Q2 is anticipated to be between $11.5 million and $14 million, reflecting year-over-year growth of 6% to 28% [12] - The company revised its 2025 guidance, expecting total revenues to grow 4-6% year over year to $650-$660 million, with adjusted EBITDA projected between $77 million and $87 million [14]

Company Overview The AI Platform for Precision Medicine May 6, 2025 Cautionary notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking state ...

Core Insights - SOPHiA GENETICS reported a strong start to 2025 with a year-over-year revenue growth of 13%, or 15% on a constant currency basis, driven by new business signed in 2024 [3][7] - The company achieved a record adjusted gross margin of 75.7%, up 520 basis points year-over-year, indicating effective cost management and operational efficiency [3][7] - The company continues to focus on long-term growth prospects, particularly in the U.S. market, where revenue from core genomics customers grew over 30% [3][13] Financial Performance - Revenue for Q1 2025 was $17.8 million, reflecting a 13% increase from $15.8 million in Q1 2024 [7][35] - Adjusted EBITDA loss improved by 24% year-over-year to $9.8 million, demonstrating progress towards profitability [7][33] - The company reaffirms its full-year revenue guidance of $72 million to $76 million, representing a growth of approximately 10% to 17% compared to FY 2024 [7][13] Business Highlights - SOPHiA DDM™ platform performed 93,000 analyses in Q1 2025, marking an 11% year-over-year volume growth [8] - The company onboarded 33 new core genomics customers in Q1 2025, up from an average of 23 customers per quarter in 2024 [8] - Significant demand for new applications, including the Liquid Biopsy application MSK-ACCESS®, has led to a healthy pipeline of over 60 identified opportunities [9][10] Market Expansion - The company expanded its collaboration with AstraZeneca to accelerate the deployment of MSK-ACCESS® globally, now involving 30 sponsored institutions [8] - New customers were signed across various geographies, including notable institutions in Belgium, Canada, and Malaysia [8][9] - The U.S. market continues to show strong business growth, with a focus on operational excellence and sustainable growth strategies [10][11]

Financial Data and Key Metrics Changes - The company reported top line results in line with expectations despite market pressures, indicating strong cash flow performance and a healthy balance sheet [4] - The revised guidance reflects a larger cut than previous ones, suggesting a cautious approach to investments in a dynamic consumer environment [7][9] Business Line Data and Key Metrics Changes - The company is prioritizing investments in marketing, R&D, and technology, focusing on increasing returns from marketing dollars and optimizing brand and media types [10][12] - The brand growth system is being scaled up to cover 40% of the business by the end of the year, indicating a strategic shift in how investments are made [12] Market Data and Key Metrics Changes - The second quarter is expected to see a top line improvement due to the timing of Easter, with an estimated positive impact of approximately 90 to 100 basis points [22] - Emerging markets are anticipated to accelerate, contributing positively to overall performance [23] Company Strategy and Development Direction - The company is committed to making necessary investments to deliver quality and value offerings, while closely monitoring market tensions [5] - The strategy includes a disciplined approach to marketing and product renovation, aiming for sustainable and profitable growth in the long term [44][59] Management's Comments on Operating Environment and Future Outlook - Management acknowledges macroeconomic uncertainties but remains confident in the strategy, choosing to invest in growth rather than adopting a defensive posture [9] - The company expects gross margin pressure in the second quarter due to increased promotional activity and commodity inflation, but anticipates recovery in the third quarter [55][56] Other Important Information - The company is facing inflationary pressures, with COGS expected to rise by 5%, influenced by commodity price increases and potential tariff impacts [33][34] - The guidance reflects a wider range to accommodate various scenarios in the changing policy landscape [63][65] Q&A Session Summary Question: Clarification on revised outlook and investment strategy - Management emphasized continued investment in the business despite macroeconomic uncertainties, focusing on marketing, R&D, and technology to drive growth [9][10] Question: Impact of Easter timing and other factors on sales - The second quarter is expected to benefit from the Easter timing shift, with improvements in specific product categories anticipated [22][23] Question: Breakdown of COGS inflation drivers - COGS inflation is expected to rise due to commodity price increases, with tariffs potentially adding 50 to 200 basis points impact [33][34] Question: Pricing strategy in response to inflation - Management is exploring various strategies to minimize price increases while maintaining profitability, including alternative sourcing and product reformulation [46][47] Question: Gross margin expectations and market share performance - Gross margin pressure is anticipated due to promotional activities and commodity inflation, but management is optimistic about growth in certain product categories [55][58]

Core Insights - SOPHiA GENETICS announced an expansion of its collaboration with AstraZeneca to enhance the global deployment of MSK-ACCESS® powered with SOPHiA DDM™, extending its reach to 30 clinical institutions in 2025 [1][3] Group 1: Collaboration and Expansion - The collaboration aims to accelerate the deployment of innovative liquid biopsy testing, which detects actionable genomic alterations from a single blood draw [2][3] - The expanded rollout will contribute to AstraZeneca's global real-world evidence initiatives and validate the clinical impact of decentralized liquid biopsy testing [3][4] Group 2: Technology and Performance - MSK-ACCESS® powered with SOPHiA DDM™ utilizes advanced algorithms to analyze circulating tumor DNA (ctDNA), supporting real-time cancer monitoring and treatment selection [2][4] - Data presented at AACR demonstrated the consistent accuracy and precision of the decentralized test across various laboratory settings, addressing historical site-to-site discordance issues [4][5] Group 3: Strategic Vision - The collaboration reflects a significant step toward scaling next-generation oncology diagnostics globally, with a shared ambition to enhance accessibility and impact of liquid biopsy technologies [5]

Group 1 - Elon Musk's xAI is reportedly negotiating to raise $20 billion, potentially valuing the company at over $120 billion, which would make it the second-largest startup financing in history, following OpenAI's $40 billion [2] - The funding could alleviate xAI's significant debt burden, with annual interest expenses exceeding $1.3 billion as of the end of last year [2] Group 2 - Manus AI has secured $75 million in funding led by Benchmark, bringing its valuation to approximately $500 million [3] - The company plans to use the funds to expand into new markets, including the United States, Japan, and the Middle East [3][4] Group 3 - Phoebe Gates has launched an AI shopping application named Phia, designed to help shoppers compare prices of clothing, shoes, and accessories [5] - The app utilizes AI to analyze current market trends and compares them with a database of 250 million second-hand items from major online resale platforms [5] Group 4 - Apple is reportedly continuing to advance its smart glasses project, codenamed "N50," which will integrate AI technology and aims to be priced affordably [6] - The smart glasses are expected to incorporate various technologies, including cameras, microphones, AI assistants, and speakers, transforming them into smart devices [6] Group 5 - AI pioneer Geoffrey Hinton and ten former OpenAI employees have issued an open letter opposing OpenAI's restructuring plan, arguing it undermines the organization's charitable mission [7] - The letter raises concerns that the restructuring could eliminate nonprofit control and key governance safeguards, potentially prioritizing profit motives over the mission of ensuring AI benefits humanity [7]